Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection

Running, not enrolling · Phase 4

Conditions studied: HIV

In brief

The purpose of this study is to identify and provide immediate antiretroviral therapy to a cohort of HIV-infected individuals with very early HIV infection (estimated date of infection within the last 90 days). The primary aim of the study is to evaluate whether initiation of dolutegravir plus emtricitabine/tenofovir during acute/early HIV infection leads to protection of CD4+ T cells and other immune cells in the peripheral blood and lymphoid tissue from infection.

Key facts

Study ID

NCT02656511

Run by

University of California, San Francisco

People needed

74

Starts

2015-12-01

Expected to finish

2028-05-01

Last updated by the study team

2026-07-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Willing and able to provide written informed consent
• Male or female, age ≥18 years
• Acute HIV infection with a negative or indeterminate HIV-1 antibody test and plasma HIV-1 RNA > 40 cp/ml, OR clinical history consistent with new HIV infection in the last 90 days.
• Antiretroviral therapy untreated or recently initiated (within 7 days)
• Participant must be able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments.
• All participants must agree not to participate in a conception process (eg, active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization)..
• When participating in sexual activity that could lead to pregnancy, female participants must agree to use a double barrier method of contraception for at least two weeks after discontinuation of study drug.

You may not qualify if…

• Known severe kidney disease (CrCl < 60 ml/min via Cockcroft-Gault method)
• Known severe hepatic impairment (Child-Pugh Class C)
• Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
• Participants with anticipated need for Hepatitis C virus (HCV) therapy during study
• Concurrent treatment with dofetilide, oxcarbazepine, phenytoin, phenobarbital, carbamazepine, St. John's wort, or metformin
• Serious illness requiring systemic treatment and/or hospitalization in the preceding 90 days prior to study enrollment
• Concurrent treatment with immunomodulatory drugs, or exposure to any immunomodulatory drugs in the preceding 90 days prior to study enrollment (e.g. IL-2, interferon-alpha, methotrexate, cancer chemotherapy)
• Concurrent treatment with investigational drugs, or exposure to any investigational drugs in the preceding 90 days prior to study enrollment
• Active drug or alcohol use or dependence that, in the opinion of the Principal Investigator, would interfere with adherence to study requirements
• Known allergy/sensitivity or any hypersensitivity to components of study drug(s) or their formulation
• Pregnant or breastfeeding women.
• For participants who agree to colorectal biopsy
• Known blood coagulation disorder
• Platelets < 50,000/mm\^3
• PTT > 2x upper limit of normal
• INR > 1.3
• Use of aspirin, NSAIDs, Plavix, Coumadin, or other blood thinners that cannot be stopped for clinical reasons for 5 days before and after each colorectal biopsy
• Inflammatory colitis (e.g., Crohn's disease and/or ulcerative colitis) and/or any contraindications to sigmoidoscopy or colorectal biopsy such as peritonitis, active diverticulitis, or recent bowel surgery

Where it is running

• San Francisco General Hospital — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.